VANCOUVER, BC, February 2, 2023 /PRNewswire/ – Platform Life Sciences, a high-impact clinical research organization with a mission to modernize clinical trials globally, has signed a key agreement with GreenLight Biosciences to support its Phase I clinical trial, GLB -003, for a novel mRNA vaccine against COVID-19 in Rwanda – which was approved today by the Rwanda FDA.
The trial will be conducted by leading clinical researchers in Rwanda, in partnership with Platform Life Sciences. Rwandan scientific leaders have conducted several clinical trials for major pharmaceutical companies and are at the forefront of advancing end-to-end research and development in Africa.
Platform Life Sciences has built a global network of innovative partnerships for running clinical trials with modern technology and infrastructure that has the potential to reduce costs and accelerate time to market for products. The network has expertise in COVID-19, vaccines, respiratory viruses and other infectious diseases.
“We share a common vision with Platform Life Sciences to work towards global self-sufficiency in vaccines and we look forward to using Platform Life Sciences in the conduct of our clinical trial,” said Andrei ZarourCEO and co-founder of GreenLight Biosciences.
In recent years, global public health has been compromised by infectious diseases and outdated clinical trial practices. Platform Life Sciences has invested in the successful development of a complex global network of community sites, designing setup and workflows with an infrastructure capable of evaluating a protocol and mobilizing Phase I, II and III trials with great efficiency. Platform Life Sciences goes where the disease is and focuses on patient populations wherever they are. Africa has been one of the fastest growing regions in the world and has substantial potential for clinical research, production and consumption – including in Rwanda.
Platform Life Sciences has also created a community of practice between its investigators and sites to ensure continuous quality improvement and innovation in the way trials are conducted and to maximize investigator engagement to conduct trials. faster and potentially accelerating access to life-saving products.
“We are delighted with the approval of this trial by the Rwandan FDA. Trust, long-term relationships and local expertise have come together to enable us to move quickly from protocol review to trial approval,” said Dr. Ed Mills, Founder and Scientific Director of Platform Life Sciences. “We look forward to this Phase I with GreenLight Biosciences as we are already working on large-scale trials that have the potential to rapidly recruit and complete clinical trials with several thousand participants.
About the life sciences platform.
For more information about Platform Life Sciences, please contact Platform Life Sciences at [email protected] or visit our website at www.platformlifesciences.com.
SOURCE Life Sciences Platform
